✦ LIBER ✦

Efficacy of carboplatin given in a phase II window study to children and adolescents with newly diagnosed metastatic soft tissue sarcoma

✍ Scribed by J.C. Chisholm; D. Machin; H. McDowell; K. McHugh; C. Ellershaw; M. Jenney; A.B.M. Foot

Book ID: 118435708
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 177 KB
Volume: 43
Category: Article
ISSN: 0959-8049
DOI: 10.1016/j.ejca.2007.08.024

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy of ifosfamide and doxorubicin g

Efficacy of ifosfamide and doxorubicin given as a phase II ?window? in children with newly diagnosed metastatic rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma Study Group

✍ Sandler, E. ;Lyden, E. ;Ruymann, F. ;Maurer, H. ;Wharam, M. ;Parham, D. ;Link, M 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 146 KB

## Abstract ## Background The cure rate for children/adolescents with localized rhabdomyosarcoma (RMS) has tripled over the past 25 years, but patients with metastatic disease at presentation have not benefited similarly, and urgently need new therapy. We evaluated a new drug pair, ifosfamide + do

9404 A Phase II study of cediranib in pa

9404 A Phase II study of cediranib in patients with metastatic gastrointestinal stromal tumours (GIST) and metastatic soft tissue sarcoma (STS) (including alveolar soft part sarcoma [ASPS])

✍ Gardner, K.; Judson, I.; Leahy, M.; Barquin, E.; Marotti, M.; Collins, B.; Young 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 50 KB

Phase II study of a protracted irinoteca

Phase II study of a protracted irinotecan schedule in children with refractory or recurrent soft tissue sarcoma

✍ Gianni Bisogno; Riccardo Riccardi; Antonio Ruggiero; Giampaolo Arcamone; Arcange 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 85 KB 👁 2 views

## Abstract ## BACKGROUND Irinotecan (CPT‐11) is a novel antineoplastic agent that takes effect by inhibiting topoisomerase I. The Italian Soft Tissue Sarcoma (STS) Committee performed a multiinstitutional Phase II study to evaluate its effect on STS. ## METHODS Over a 2‐year period between 2002

Brostallicin, an agent with potential ac

Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: A phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group

✍ Michael Leahy; Isabelle Ray-Coquard; Jaap Verweij; Axel Le Cesne; Florence Duffa 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 166 KB

A pilot study of low-dose anti-angiogeni

A pilot study of low-dose anti-angiogenic chemotherapy in combination with standard multiagent chemotherapy for patients with newly diagnosed metastatic Ewing sarcoma family of tumors: A Children's Oncology Group (COG) Phase II study NCT00061893

✍ Felgenhauer, Judy L.; Nieder, Michael L.; Krailo, Mark D.; Bernstein, Mark L.; H 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 94 KB

Randomized Phase II Study of Gemcitabine

Randomized Phase II Study of Gemcitabine and Docetaxel Compared With Gemcitabine Alone in Patients With Metastatic Soft Tissue Sarcomas: Results of Sarcoma Alliance for Research Through Collaboration Study 002

✍ Maki, R. G.; Wathen, J. K.; Patel, S. R.; Priebat, D. A.; Okuno, S. H.; Samuels, 📂 Article 📅 2007 🏛 American Society of Clinical Oncology 🌐 English ⚖ 163 KB